Nievel J G, Harvard C W
Curr Med Res Opin. 1981;7(8):526-35. doi: 10.1185/03007998109112369.
The efficacy and acceptability of single daily doses of a fixed combination of 400 mg acebutolol and 25 mg hydrochlorothiazide were assessed in an open study of 30 patients suffering from mild to moderate essential hypertension. Results from 20 patients who completed the 6-months' active drug period, and 9 patients whose treatment was terminated at various times before the end of this period, indicated significant reduction in the systolic and diastolic blood pressure in supine, sitting and standing positions. This effect was apparent from the first month on drug therapy and was maintained throughout the 6-month trial. In no patient was withdrawal from this study attributable to side-effects of the drug. Results indicated good control of hypertension by a single dose of the combined drugs and good patient compliance was observed during the study. Potassium loss, frequently experienced during hydrochlorothiazide treatment, was not observed in the presence of acebutolol.
在一项针对30例轻至中度原发性高血压患者的开放性研究中，评估了每日单次服用400毫克醋丁洛尔与25毫克氢氯噻嗪固定组合的疗效和可接受性。20例完成6个月活性药物治疗期的患者以及9例在此期间结束前不同时间终止治疗的患者的结果表明，仰卧位、坐位和站立位的收缩压和舒张压均显著降低。这种效果从药物治疗的第一个月就很明显，并在整个6个月的试验中持续存在。没有患者因药物副作用而退出本研究。结果表明，单次服用联合药物可有效控制高血压，并且在研究期间观察到患者依从性良好。在使用醋丁洛尔的情况下，未观察到氢氯噻嗪治疗期间常见的钾流失现象。
